Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
herpes zoster vaccine (recombinant, adjuvanted) (GSK)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- intramuscular
01
Overview
Shingrix (herpes zoster vaccine (recombinant, adjuvanted)) is a non-live, recombinant subunit vaccine developed by GSK for the prevention of herpes zoster (shingles) and post-herpetic neuralgia (PHN). The vaccine consists of a purified recombinant varicella-zoster virus (VZV) glycoprotein E (gE) antigen combined with the proprietary AS01B adjuvant system. The AS01B adjuvant system contains QS-21 (a purified plant saponin extract from *Quillaja saponaria*) and 3-O-desacyl-4'-monophosphoryl lipid A (MPL), which work synergistically to activate innate immune pathways and enhance antigen presentation. This formulation is designed to elicit a robust, long-lasting antigen-specific cellular and humoral immune response, helping to overcome the natural age-related decline in immunity. It is administered intramuscularly as a two-dose series.
- Brand names
- Shingrix
- Other names
- HZ/suPED-HZ/surecombinant herpes zoster vaccinerecombinant zoster vaccinezoster recombinant adjuvantedzoster vaccine recombinant, adjuvanted
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on herpes zoster vaccine (recombinant, adjuvanted) (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on herpes zoster vaccine (recombinant, adjuvanted) (GSK).